Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 54Terminated 23Unknown 9Recruiting 8Active not recruiting 7Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 3Sarcoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Liver Neoplasms 1Leukemia, Plasma Cell 1Desmoid Tumors 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 10Paclitaxel 8Bevacizumab 7Cyclophosphamide 6olaparib 5niraparib 5Fulvestrant 4talazoparib 3Radiotherapy 3Gemcitabine 3Capecitabine 3veliparib 2palbociclib 2eribulin 2dostarlimab 2aldesleukin 2Trastuzumab 2Specimen Handling 2Letrozole 2Drug Therapy 2Doxorubicin 2Cisplatin 2Celecoxib 2Biopsy 2Albumin-Bound Paclitaxel 2tucotuzumab celmoleukin 1trastuzumab duocarmazine 1trastuzumab biosimilar HLX02 1sotigalimab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ovarian Neoplasms × liposomal doxorubicin × Clear all
NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Millennium Pharmaceuticals, Inc.

Phase 2 Withdrawn
91 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡